Events

Power Cross .018 OTW PTA Dilatation Catheter 에 대한 현장 안전성 서한

Health Sciences Authority (HSA)에 따르면, 해당 현장 안전성 서한 는 Singapore 에서 Covidien Private Limited 에 의해 제조된 제품과 관련되어 있습니다.

이것은 무엇인가요?

현장 안전성 서한은 의료기기 제조사 또는 제조사 대리인이 시중에 유통되고 있는 자사 의료기기 제품에 대하여 취할 수 있는 조치를 알리는 소통방식입니다. 주요 대상층은 보건의료업계 종사자와 의료기기 사용자들입니다. 여기에는 회수(recall) 조치와 경고도 포함될 수 있습니다.

데이터에 대해 더 자세히 알아보기 여기
  • 사례 유형
    Field Safety Notice
  • 사례 ID
    600:41/01-046/16/03_17
  • 날짜
    2016-03-31
  • 사례 국가
    Singapore
  • 사례 출처
    HSA
  • 사례 출처 URL
    https://www.hsa.gov.sg/announcements
  • 비고 / 경고
    Data from Singapore is current through September 2018. All of the data comes from the Health Sciences Authority (HSA), except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of recall data from the U.S. and Singapore.
  • 데이터 추가 비고
    ev3 Inc

Device

Power Cross .018 OTW PTA Dilatation Catheter
  • 모델명 / 제조번호(시리얼번호)
  • 제품 설명
    Power Cross .018 OTW PTA Dilatation Catheter, ev3 Inc
  • Manufacturer
    Covidien Private Limited

Manufacturer

Covidien Private Limited
  • 제조사 모회사 (2017)
    Medtronic plc
  • 제조사 의견
    “If our surveillance systems identify a potential performance issue, our personnel promptly evaluate the problem, including, when appropriate, conducting root cause investigations and internal testing to assess whether the product continues to meet specifications and defined performance criteria,” Medtronic told ICIJ in a statement. “In some cases, based on this evaluation, Medtronic may determine that a recall is necessary.” The company said that it communicates with healthcare providers and/or patients and provide recommendations to address such issues. Medtronic noted that these communications can include letters, emails, calls, press releases, physician notifications and social media postings, as well as informing the FDA and other regulators of the actions.
  • Source
    HSAHSA